Healthcare | November 18, 2022
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Results reinforce commitment to next-generation oral SERD development programme
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Prime Minister said that it is a huge day for health in Gujarat and congratulated everyone associated with these projects for completing them on time.
Subscribe To Our Newsletter & Stay Updated
